Leede Financial Issues Positive Outlook for TSE:MDP Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities researchers at Leede Financial lifted their FY2028 earnings per share estimates for shares of Medexus Pharmaceuticals in a research note issued to investors on Monday, December 2nd. Leede Financial analyst D. Loe now anticipates that the company will post earnings per share of $1.15 for the year, up from their previous estimate of $1.14. Leede Financial currently has a “Speculative Buy” rating and a $8.25 price target on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

Several other brokerages have also recently commented on MDP. Raymond James upgraded Medexus Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the stock from C$3.00 to C$4.00 in a report on Wednesday, November 20th. Stifel Nicolaus boosted their price target on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Finally, Stifel Canada upgraded Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Monday, August 12th. Three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of C$5.25.

Medexus Pharmaceuticals Stock Up 2.5 %

Shares of Medexus Pharmaceuticals stock opened at C$2.82 on Tuesday. Medexus Pharmaceuticals has a 12-month low of C$1.44 and a 12-month high of C$3.16. The firm has a market capitalization of C$69.17 million, a PE ratio of 56.40 and a beta of 1.96. The stock’s fifty day moving average is C$2.47 and its 200-day moving average is C$2.24.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.